ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2016
Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Guideline
- Therapeutic value of lymph node dissection for Siewert type II and III adenocarcinoma: meta-analysis.BJS open · 2024Pooled it
- Establishing a standard surgery for esophagogastric junction cancer: Final results from the JGCA-JES nationwide prospective study.Cell reports. Medicine · 2026Trial
- Biological Characteristics and Therapeutic Strategies for Resectable Locally Advanced Esophagogastric Junction Cancer: A Comprehensive Update.Journal of gastric cancer · 2026Review
- Review
- Surgical and Perioperative Treatments for Esophagogastric Junction Cancer.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2024Review
- Essential updates 2021/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer.Annals of gastroenterological surgery · 2023Review
- Management of Esophago-Gastric Junction Carcinoma: A Narrative Multidisciplinary Review.Cancers · 2023Review
- Comparison of lymph node metastasis pattern from esophagogastric junction adenocarcinoma versus very low thoracic esophageal squamous cancer: a propensity-matched analysis.Journal of thoracic disease · 2023Article
- Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report.Translational cancer research · 2022Article
- LaparoscopicChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
- Clinical significance of lower perigastric lymph nodes dissection in Siewert type II/III adenocarcinoma of esophagogastric junction: a retrospective propensity score matched study.Langenbeck's archives of surgery · 2022Article
- Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Feasibility of Preserving No. 5 and No. 6 Lymph Nodes in Gastrectomy of Proximal Gastric Adenocarcinoma: A Retrospective Analysis of 395 Patients.Frontiers in oncology · 2022Article
- Mapping of lymph node dissection determined by the epicenter location and tumor extension for esophagogastric junction carcinoma.Frontiers in oncology · 2022Review
- Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma.Cancer medicine · 2021Article
- Risk factor of mediastinal lymph node metastasis of Siewert type I and II esophagogastric junction carcinomas.Langenbeck's archives of surgery · 2020Article
- Laparoscopic and left thoracoscopic Ivor-Lewis esophagectomy for Siewert type II esophagogastric junction cancer with right aortic arch: a case report.Surgical case reports · 2020Article
- True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends.Surgery today · 2020Review
- Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study.World journal of surgical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsThe aim of this study was to evaluate the theoretical therapeutic impact of dissecting each lymph node station for adenocarcinoma and squamous cell carcinoma of the esophagogastric junction.
methodsThis multicenter study included 431 junctional cancer patients (381 adenocarcinomas and 50 squamous cell carcinomas) who fulfilled the following criteria: (1) the center of the tumor was located between 1 cm above and 2 cm below the esophagogastric junction, and (2) the tumor invaded the junction. The theoretical therapeutic impact of dissecting each lymph node station was evaluated based on the therapeutic value index calculated by multiplying the frequency of metastasis to each station and the 5-year survival rate of patients with metastasis to that station.
resultsThe 5-year overall survival rates (95% confidence interval) were 60.4% (55.1-65.7) in the adenocarcinoma cases and 52.3% (35.6-69.0) in the squamous cell carcinoma cases. The nodal stations showing the first to fifth highest index were the paracardial and lesser curvature nodes (nos. 1, 2 and 3), nodes at the root of the left gastric artery (no. 7) and lower mediastinal lymph nodes, regardless of the histology.
conclusionsNodal dissection achieved by proximal gastrectomy and lower esophagectomy should be the minimal requirement for junctional cancer regardless of the histology, considering the therapeutic value indices for the relevant lymph node stations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.